Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Short-term Investments: 2017-2024

Historic Short-term Investments for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $828.0 million.

  • Arcus Biosciences' Short-term Investments fell 33.22% to $593.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $593.0 million, marking a year-over-year decrease of 33.22%. This contributed to the annual value of $828.0 million for FY2024, which is 31.01% up from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' Short-term Investments is $828.0 million, which was up 31.01% from $632.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Short-term Investments ranged from a high of $828.0 million in FY2024 and a low of $351.0 million during FY2021.
  • Over the past 3 years, Arcus Biosciences' median Short-term Investments value was $803.0 million (recorded in 2022), while the average stood at $754.3 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 326.01% in 2020, then tumbled by 36.78% in 2021.
  • Over the past 5 years, Arcus Biosciences' Short-term Investments (Yearly) stood at $555.2 million in 2020, then plummeted by 36.78% to $351.0 million in 2021, then surged by 128.77% to $803.0 million in 2022, then decreased by 21.30% to $632.0 million in 2023, then soared by 31.01% to $828.0 million in 2024.